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Abstract 
Deregulation of signaling pathways involving phosphorylation is a hallmark of malignant 
transformation.  Degradation of phosphoproteins generates cancer-specific phosphopeptides that 
are associated with MHC-I and II molecules and recognized by T-cells. We identified 95 
phosphopeptides presented on the surface of primary hematological tumors and normal tissues, 
including 61 that were tumor-specific.  Phosphopeptides were more prevalent on more 
aggressive and malignant samples.  CD8 T-cell lines specific for these phosphopeptides 
recognized and killed both leukemia cell lines and HLA-matched primary leukemia cells ex vivo.  
Healthy individuals showed surprisingly high levels of CD8 T-cell responses against many of 
these phosphopeptides within the circulating memory compartment. This immunity was 
significantly reduced or absent in some leukemia patients, which correlated with clinical 
outcome, and was restored following allogeneic stem cell transplantation. These results suggest 
that phosphopeptides may be targets of cancer immune surveillance in humans, and point to their 
importance for development of vaccine-based and T-cell adoptive transfer immunotherapies.. 
One-sentence summary 
In this work we characterize 95 leukemia-associated phosphopeptide antigens and show that 
healthy donors exhibit unexpected immunity against many of these which is lacking in patients 
with leukemia but can be restored following stem cell transplantation. 
 
Introduction 
Hematologic malignancies are susceptible to curative immunological therapies, such as stem cell 
transplantation, donor lymphocyte infusion and manipulation of endogenous immunity through 
immunostimulatory cytokines (1-4). The clinical utility of cellular immunotherapies provides 
powerful direct evidence that the adaptive immune response can control and eradicate tumors(5-
9). However, immunotherapies targeting identified tumor antigens have met with limited 
success, suggesting the optimal antigens remain undiscovered (10-12). Moreover, the vast 
majority of identified tumor antigens are not derived from oncoproteins orchestrating the 
transformation process. Efforts targeting these antigens may be compromised by tolerance 
mechanisms and immune escape. 
 The importance of signal-transduction pathway deregulation in cancer pathogenesis is 
well-established (13-17). Small molecule therapies targeting these pathways have met with 
considerable clinical success, providing a powerful argument for immunotherapies that target 
similar deregulated pathways (18-20). Protein phosphorylation is the dominant mechanism 
involved in oncogenic signaling processes (21). We previously showed that phosphorylation is 
preserved on peptides during antigen processing for presentation by both MHC-I and –II 
molecules (22-24). This suggests that phosphopeptide antigens derived from cancer-related 
phosphoproteins could serve as immunological signatures of 'transformed self' (22-26). 
Moreover, phosphorylation can enhance the binding of peptides to MHC-I molecules, creating 
“neo-antigens”. Collectively these results suggest that phosphopeptides are attractive targets for 
cancer immunotherapy (27).  
To date, no studies have examined MHC-I-bound phosphopeptides displayed on primary 
human tumor samples, nor has the human immune response against MHC-I restricted 
phosphopeptides been characterized. Here, we identify novel phosphopeptides from primary 
leukemia samples and show that healthy individuals display immune responses with memory 
characteristics against many of them. Immunity is lost in some patients with leukemia, but can be 
restored. This unexpected pre-existing immunity to phosphopeptides suggests that they could be 
targets of immune surveillance, and play a role in enabling immunological control of 
malignancies in humans. 
 
Results 
Characterization of Leukemia-Associated MHC Class-I Restricted Phosphopeptides 
To identify tumor-associated phosphopeptides, we affinity-isolated HLA-A*0201 (HLA-A2) and 
HLA-B*0702 (HLA-B7) peptide complexes from 4 primary chronic lymphocytic leukemia 
(CLL) tumors, a primary hairy-cell leukemia (HCL), a primary mantle cell lymphoma (MCL), a 
primary acute lymphoblastic leukemia (ALL), and a primary acute myeloid leukemia (AML), in 
addition to normal splenic T and B-cells, bone marrow cells (BM), and cultured B-
lymphoblastoid cell lines (B-LCL). Collectively, 10 HLA-A2-restricted and 85 HLA-B7-
restricted phosphopeptides were identified (Fig. 1a). All tumor types and normal tissues 
expressed a greater number of HLA-B7 than HLA-A2 phosphopeptides (Fig. 1b).  
The large number of HLA-B7-restricted phosphopeptides enabled us to compare their 
representation on different tumor types and healthy tissue. On average more than twice as many 
were found on aggressive (AML and ALL) as on indolent (CLL and HCL) tumors or normal 
tissue (Fig. 1c). Of 56 HLA-B7-restricted phosphopeptides identified on AML, 36 were not 
found on any other leukemia and only two were found on bone marrow (Figs. 1a, 2a). Of 45 
phosphopeptides identified on ALL, 19 were not found on other leukemias and 13/19 were also 
not observed on T- or B-cells (Fig. 2a). Seven were derived from oncogenes implicated in 
leukemogenesis: MYC, EP300, SKI, GFI-1, Bcl-11A, MEF2D, and MLL (Fig. 1a). Twenty-
seven HLA-B7 phosphopeptides were identified on two CLL tumors, all of which were shared 
with either AML or ALL. Sixteen were observed on normal tissue but seven were common to 
AML, ALL and CLL and not normal tissue (CCDC45, GRK2, SETD2, C17orf85, TSC22D4 and 
SPR(pS)PGKPM, derived from an unknown protein). These proteins have not been previously 
associated with leukemic malignancies and the functions of most remain undefined. Twenty-six 
of 27 CLL peptides were also found on HCL, which itself expressed one additional unique 
phosphopeptide. Twenty-four of these were also shared by B-LCL (Fig. 2b). These results 
identify a cohort of phosphopeptides expressed on multiple leukemic malignancies, but not 
normal tissue, which represent potential immunotherapeutic targets. 
 Characteristics of the HLA-A2 bound phosphopeptides were similar to those previously 
reported (22, 23). Of 85 HLA-B7-restricted phosphopeptides, two were dually phosphorylated 
and the remainder monophosphorylated, with 77/85 containing phosphoserine and 9/85 
containing phosphothreonine. The phosphate was found at position four in 72% of HLA-B7 
phosphopeptides, similar to the distribution in HLA-A2 phosphopeptides (Fig. S1a,b) (27). 
When compared with 1038 non-phosphorylated HLA-B7-restricted 9mer peptides in the 
ImmuneEpitope database (28), HLA-B7-restricted phosphopeptides showed a similar strong 
preference for proline at P2 and common hydrophobic C-terminal anchor residues (Fig. 2c, d). 
However, they showed an unusual bias for basic residues at P1 and proline at P5 (Fig 2c, Fig. 
S1c). To test whether these biases were imposed by an underlying kinase recognition motif, 
potential HLA-B7 binding 9mer peptides were identified in the Phosphosite dataset (29) of 
known serine phosphorylation sites. The position of the phosphoserine within 1031 
phosphopeptides predicted to bind to HLA-B7 was not skewed towards P4 (Fig. 2e). Thus, these 
biases likely reflect roles in binding to HLA-B7 analogous to those demonstrated for HLA-A2-
associated phosphopeptides (27). Of 164 predicted HLA-B7 binding peptides that had 
phosphoserine at P4 there was no apparent bias for basic residues at P1 (Fig. 2f). However 87% 
contained a proline at P5 suggesting this bias reflects an underlying kinase motif, rather than 
being imposed by HLA binding.  
 
Phosphopeptide-specific T-cell responses in healthy donors 
Three HLA-A2 and two HLA-B7 phosphopeptides were derived from LSP-1, a lymphoma 
marker (30). One, RQA(pS)IELPSMAV, is present on all HLA-A2
+
 tumor samples at high copy 
number. RQA(pS)IELPSMAV-pulsed dendritic cells were used to prime autologous T-cells. 
Responses to this phosphopeptide could be elicited in 3/3 healthy individuals. Specific T-cells 
were enriched using HLA-A2- RQA(pS)IELPSMAV tetramers to produce T-cell lines (Fig. 3a). 
These lines secreted IFNγ in response to stimulators pulsed with RQA(pS)IELPSMAV, but not 
with unphosphorylated RQASIELPSMAV, nor to other phosphopeptides, including the closely 
related RQA(pS)IELPSM (Fig. 3b). Recognition was therefore both phosphate-dependent and 
peptide sequence-specific. These lines also killed the HLA-A2
+
 AML cell line THP-1 and the 
HLA-A2 transfected ALL cell line, Jurkat-A2, but not untransfected Jurkat (Fig. 3c-d). Most 
importantly, RQA(pS)IELPSMAV-specific T-cells killed HLA-A2
+
 primary AML and CLL 
tumors, but not an HLA-A2
neg
 CLL tumor (Fig. 3e). T-cell lines were also elicited against an 
HLA-B7 restricted phosphopeptide (RPT(pS)RLNRL) derived from NCOA-1 and showed 
remarkable phosphopeptide-specific killing of three primary CLL tumors (Fig. 3f).   
 We next evaluated immunity in 10 healthy donors against 10 HLA-A2 and 76 HLA-B7 
leukemia-associated phosphopeptides (Fig. 4a). Immune responses to 50/76 HLA-B7 and 9/10 
HLA-A2 phosphopeptides were observed. Each individual responded to an average of 16/76 
(range 11-22) HLA-B7 and 2/10 (range 0-4) HLA-A2 phosphopeptides. Importantly, these 
responses were observed in 7-day in vitro cultures without addition of exogenous cytokines. No 
responses of a similar magnitude were observed for several phosphopeptides encoded by well-
established leukemia oncogenes, most notably MYC, BCL-11A and EP300. However, the MYC 
and BCL-11A phosphopeptides were also present on normal T-cells (Fig. 1a). Phosphopeptides 
from other leukemia oncogenes (MLL, LPP, SKI, GFI-1 and MEF2D) elicited strong immune 
responses in several individuals. There was substantial donor to donor variation as to which 
phosphopeptides stimulated these unusually strong responses: the GFI1 phosphopeptide 
stimulated responses in 9/10 individuals; the MLL, LPP, and MAP3K11 phosphopeptides in 
8/10; and those from LSP1, SCAP and RBM15 in 7/10. For four phosphopeptides that were 
recognized by most healthy donors, T-cell specificity was confirmed in 14-day cultures using 
HLA-phosphopeptide multimers (Fig. 4b).  Furthermore, these T-cells did not recognize the 
unphosphorylated counterpart peptides (Fig. 4c, Fig. S2). Collectively, these data demonstrate 
that the majority of leukemia-associated phosphopeptides elicited surprisingly strong and 
specific responses in a significant fraction of healthy individuals. 
 
Leukemia-associated phosphopeptide-specific immunity in healthy donors. 
Because responses to phosphopeptides were observed after only 7 days of in vitro culture in the 
absence of exogenous cytokines, we compared them with responses to immunodominant 
epitopes from three persistent viruses (CMV, EBV and HSV) and two non-persistent viruses 
(influenza and adenovirus). Responses against four phosphopeptides were even evident in ex 
vivo ELISpot analysis of peripheral blood mononuclear cells (PBMC) from some donors (Fig. 
4b,d). These responses were similar to, or higher than, those to both non-persistent viral 
epitopes, but lower than responses to CMV and EBV epitopes. This high level of 
phosphopeptide-specific T-cells led us to investigate whether the responding cells resided within 
memory or naïve T-cell compartments. Enriched CD8 T-cells from peripheral blood of two 
HLA-B7
+
 healthy donors were flow-sorted into naïve (TN), central memory (TCM), effector 
memory (TEM) and terminal effector memory cells (TEMRA) based on expression of CD45RA and 
CD27 (31). After 7-day in vitro culture, ELISpot analysis demonstrated that T-cells responding 
to individual phosphopeptides were exclusively in the memory compartment, and predominantly 
had a TCM phenotype (Fig. 4e, Fig. S3). This suggests that the majority of healthy individuals 
have been previously exposed to a stimulus that establishes immunological memory to tumor-
associated phosphopeptides.  
Absent phosphopeptide-specific immunity in leukemia patients. 
We next evaluated the level of phosphopeptide-specific CD8 T-cell immunity in 
immunocompetent patients with early-stage CLL (Table S1). As tumor cells are present at high 
levels in PBMC from CLL patients, comparison with responses in PBMC from healthy 
individuals is problematic. Therefore, responses against a group of 12 CLL-associated 
phosphopeptides (identified by red dots in Fig. 1) were assessed by direct ex vivo ELISpot of 
purified CD8 T-cells (Fig. S4). As expected, we detected immune responses to most of these 
phosphopeptides in all 10 healthy HLA-B7
+
 individuals (Fig. 5a). However, 9/14 CLL patients 
(Group 1) had low or absent immunity to all 12 phosphopeptides (less than a combined total of 
10 spots for all 12 phosphopeptides/200,000 CD8 T-cells). Five CLL patients (Group 2) showed 
breadth of recognition of different phosphopeptides similar to that of the healthy donors. 
However, average responses to all phosphopeptides were significantly lower in Group 2 patients 
than in healthy individuals (Fig 5b).  
This lack of phosphopeptide-specific immunity in CLL patients might have been due to 
an overall depression of T-cell immunity. However, bulk CD8 T-cell responses to low level anti-
CD3 were comparable in Group 1 and 2 patients and healthy donors (Fig. 5c).  To assess 
whether the lack of phosphopeptide-specific immunity in Group 1 patients reflected T-cell 
anergy, we analyzed patient responses to the pNCOA-1 phosphopeptide, which is immunogenic 
in 9/10 healthy donors, in the presence of IL-2 as this cytokine has been shown to reverse the 
anergic state (32). Responses to anti-CD3 increased in the presence of IL-2, but no anti-
phosphopeptide immunity was detected (Fig. S5). This suggests that pre-existing phosphopeptide 
immune T-cells in Group 1 patients had been deleted, or had never developed, rather than being 
anergized.  
Although CLL is a less aggressive tumor than either AML or ALL, the disease is more 
aggressive in a subgroup of patients. Thus, we assessed whether the level of phosphopeptide-
specific immunity was associated with patient outcome. Despite selecting patients with early 
stage disease, there were large differences in progression-free survival, overall survival and time 
to first treatment between Group 1 and Group 2. Group 2 patients survived longer and required 
less treatment than Group 1 patients (Figs. 5d-f). However, due to the small study size these 
differences did not reach statistical significance. 
We extended these studies to a cohort of 12 HLA-B7
+
 AML patients in complete 
remission (Table S2) using a panel of 12 AML-specific phosphopeptides (green dots in Fig. 1). 
Responses to most of these phosphopeptides were detected in 12 healthy donors after 7-day in 
vitro culture (Fig. 6a, Fig. S6).  However, as with CLL patients, the average responses of AML 
patients to individual phosphopeptides were significantly lower (Fig 6b, P<0.0001). AML 
patients could also be stratified: Group 1 patients (10/12) showed a profound lack of 
phosphopeptide-specific immunity, while Group 2 (2/12) showed responses that were similar to 
those of normal donors. Again, responses to low dose anti-CD3 were similar between the groups, 
indicating that the lack pre-existing anti-phosphopeptide responses in patients is not due to 
immune incompetence (Fig. S6). In keeping with this, absolute lymphocyte counts for all 12 
AML patients were within the normal range pre-transplant (Table S2). Collectively, these 
findings demonstrate that the majority of patients with either CLL or AML have reduced pre-
existing immunity specific for leukemia-associated phosphopeptides.  
 
Restoration of phosphopeptide-specific immunity after stem cell transplantation 
(SCT). 
A graft versus leukemia (GvL) response following allogeneic SCT correlates with a positive 
clinical outcome in AML patients. While it is believed that GvL is directed to minor 
histocompatibility antigens (mHAgs), the targets have been only partly identified (32). We 
hypothesised that SCT might also reconstitute potentially protective immunity against leukemia-
associated phosphopeptides in AML patients. All 12 AML patients went on to have allogeneic 
SCT. Immunity against the 12 AML-specific phosphopeptides was at least partly restored in the 
majority of patients studied (Fig. 6c, Fig. S5). Marked expansion of immune responses to six 
different phosphopeptides was observed in patient AML2 (Fig. 6d), while patient AML4 showed 
dramatic expansion of responses to MLL(EPR) and LSP1(QPR) phosphopeptides, and modestly 
increased responses to C17orf85 and SKI (Fig 6e).  Some of these responses were as large as 
those against an immunodominant CMV epitope (pp65) and the resulting T-cells bound HLA-
phosphopeptide tetramers.  Furthermore, in vitro expanded MLL(EPR)-specific T-cells from 
patient AML4 killed AML cells (Fig. 6f) confirming their functional relevance. These data 
reveal a linkage between immunity to leukemia-associated phosphopeptides and GvL following 
allogeneic SCT 
 
Discussion 
Posttranslationally modified antigens are increasingly being shown to play important roles in 
human disease (33-37). Here we have tested the hypothesis that phosphopeptide neoantigens 
could be identified on primary human malignant tissue and would be immunogenic in healthy 
donors or patients with cancer.  We now report 95 phosphopeptides displayed on the surface of 
primary hematological malignant tissue in association with two dominant human MHC-I 
molecules. We observed substantial differences in the number of phosphopeptides presented by 
different HLA alleles, although the underlying mechanism for these differences is unclear. Our 
results establish that MHC-I displayed phosphopeptides are over-represented on multiple 
leukemic malignancies, and that more aggressive malignancies display a greater diversity of 
them. Many of these tumor-associated phosphopeptides are derived from oncogenes linked to 
leukemogenesis, making these of particular interest as immunotherapeutic targets.   
 Unexpectedly, many of these phosphopeptides were the targets of pre-existing immunity, 
based on high levels of responding CD8 T-cells with a predominantly central memory 
phenotype. The levels of responding cells were similar to those directed against 
immunodominant epitopes from some non-persistent viruses. These T-cells, when expanded in 
vitro, bound to HLA-B7-phosphopeptide tetramers, and recognized and killed primary tumor 
cells, suggests they were high avidity. These observations contrast with those reported for other 
tumor-associated antigens. Immunity to cancer-testis antigens is generally not present in healthy 
individuals, and becomes detectable in patients with cancer, but is associated with a poor 
prognosis (38, 39).  Immunity to tissue-associated differentiation antigens, particularly those 
defined as targets for melanoma-specific T-cells, is also elevated in melanoma patients (40, 41), 
but is believed to be compromised by self-tolerance (42, 43). Importantly, none of the healthy 
donors in which these memory-compartment associated immune responses were evident showed 
any signs of autoimmune disease. This suggests that these phosphopeptides are displayed on 
normal tissue at levels that are substantially lower than those on tumors. In keeping with this, T-
cells specific for LSP1 (RQAV) and NCOA-1 recognize tumors, but not resting B-cells, despite 
the presence of these epitopes on the latter cells.  
 Although a small study, these findings suggest that the majority of healthy individuals 
have been previously exposed to a stimulus that establishes immunological memory to 
substantial numbers of phosphopeptides. For a small number of these phosphopeptides, 
immunological memory is prevalent among most individuals examined. The mechanism that 
underlies the development of phosphopeptide-specific memory CD8 T-cells is of great interest. 
While it is possible that a distinct, cross-reactive stimulus could be responsible for the 
development of a generic phosphate-directed immunity, all of the T-cells studied to date are 
specific for the phosphate, the specific peptide sequence, and the MHC molecule that presents it. 
On the other hand, hematolymphoid transformation by Epstein-Barr virus (EBV) is ubiquitous in 
humans, and T cell immunosuppressed individuals commonly develop EBV-related 
malignancies (44). This points to ongoing immune surveillance directed against virally-
transformed, and not just virally infected, cells. While much of this is directed at latent EBV 
gene products, T-cells directed against EBV transformed cells also recognize EBV negative 
tumors (45). We hypothesize that phosphopeptides that are shared by different kinds of 
malignancies are among the targets of these T-cells. In addition, molecular techniques have 
shown that 69% of healthy individuals have detectable myeloid-transforming transcripts in 
peripheral blood (46), and 5-12% of healthy individuals show a monoclonal B-cell 
lymphocytosis, a recognized precursor of CLL (47, 48). Finally, since some of these 
phosphopeptides are also found on cell lines from solid tumor malignancies (22) , immune 
surveillance against a broad range of early-stage non-hematopoietic cancers may also lead to the 
development of phosphopeptide-specific immune memory. The extensive variation among 
individuals in which phosphopeptides are the targets of this pre-existing immunity is consistent 
with immune surveillance operating on the unique tumors that arise in each person. While it is 
difficult to prove definitively in humans, we hypothesize that phosphopeptide-specific memory 
cells are evidence of previous encounters with nascent tumors that have deregulated some of 
their phosphorylation-based signaling cascades.  
 Interestingly, the majority of patients with CLL and AML lacked evidence of pre-existing 
immunity to substantial subsets of phosphopeptides, and the clinical outcome was more 
favorable in CLL patients where phosphopeptide immunity was present. It is possible that the 
lack of phosphopeptide-specific immunity reflects a lack of exposure during the immune 
surveillance phase preceding tumor development. Alternatively, it may reflect the operation of 
immunosuppressive mechanisms, or the occurrence of clonal exhaustion, in conjunction with 
tumor outgrowth. Regardless of the exact mechanism, the results point to a role for 
phosphopeptide-specific immunity as a component of tumor recognition and control. 
 Although the antigenic targets for the GvL response include mHAgs (49-51), multiple 
studies have revealed that SCT between identical twins, where mHAg differences are not 
present, can lead to curative outcomes (52-54). In AML, deficient phosphopeptide-specific 
immunity could be restored following adoptive transfer of T-cells from a stem cell donor. This 
indicates that immunity against phosphopeptide tumor antigens may define a component of the 
GvL response (1, 5). It is known that survival of CMV+ patients can be enhanced by pre-
selecting donors for SCT who have pre-existing CMV-specific immunity (55). It is therefore 
possible SCT outcome may also be improved by matching donors with pre-existing immunity to 
particular phosphopeptides based on the display of phosphopeptides on leukemia cells.  
In this present study we have been unable to demonstrate a direct causal relationship between the 
lack of cellular immunity against phosphorylated antigens in patients, with disease development 
and/or progression.   Neither have we been able to connect, at the molecular level, deregulated 
oncogenic signaling present in each primary tumor, to the phosphorylation events present within 
the defined antigens.  Larger, more complex and extensive studies, will be needed to define these 
relationships. Collectively, however, our results suggest that the display of MHC-associated 
phosphopeptides may play a role in preventing either the development or progression of 
malignant disease. Thus, enhancing immunity to these tumor-associated antigens should become 
a focus of future cancer immunotherapeutic strategies. 
 
Materials and Methods 
Tumor samples and cell lines. Blood or leukapheresis samples were taken from patients with 
high-burden leukemia in heparin, and tumor cells were isolated on Ficoll density gradients. The 
purity of the tumor was >98% pure in all cases as assessed by flow cytometry. Healthy T and B-
cell populations were isolated from normal spleen and tonsil samples processed by mechanical 
disruption, followed by density gradient separation and enrichment using anti-CD19 or anti-CD3 
microbeads (Miltenyi Biotec) to >98% purity. Bone marrow sample was obtained from an 
elective orthopedic procedure and red cell depleted using hypotonic lysis. All cell lines were 
grown at 37°C with 5% CO2 in medium consisting of RPMI-1640 supplemented with 10% Fetal 
Bovine Serum (FBS) and 2 mM L-glutamine (all from Sigma-Aldrich).  
Isolation of HLA-associated peptides. Class-I MHC molecules were immunoaffinity purified 
from samples, and their associated peptides were extracted, as described(22). Briefly 1.2 to 14 
x10
9
 cells were lysed in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% CHAPS, 1 mM PMSF, 5 
μg/mL aprotinin, 10 μg/mL leupeptin, 10 μg/mL pepstatin A, 1 µg/ml calyculin A (Sigma-
Aldrich) and phosphatase inhibitor cocktails I and II (Sigma-Aldrich). For primary tumors or the 
HLA-A2, B7 homozygote B-LCL JY the mixture was centrifuged at 100, 000 x g for 1 hour and 
the resulting supernatant was passed over protein A Sepharose pre-loaded with the HLA-A2-
specific antibody BB7.2 or HLA-B7-specific antibody ME1. For the HLA-A3, B7 homozygous 
B-LCL GM03107 columns were loaded with the HLA-B, C specific antibody B123.2 to recover 
HLA-B7 molecules. Peptides were eluted from the purified class-I MHC molecules with 10% 
acetic acid and separated by ultrafiltration (ULTRAFREE-MC, Millipore). 
Sequence analysis of HLA-Associated Phosphopeptides. Immunoaffinity-purified class I 
peptides were converted to d0- or d3-methyl esters and subjected to Fe
+3
-immobilized metal-
affinity chromatography to isolate phosphopeptides, as described(22).  Phosphopeptide methyl 
esters were then analyzed by a combination of nanoflow HPLC, microelectrospray ionization, 
and collision activated dissociation on LTQ/FT or Orbitrap tandem mass spectrometers (Thermo 
Scientific)(22). Electron transfer dissociation (ETD) spectra were acquired on an in-house 
modified LTQ mass spectrometer(56).  Peptide sequences were determined by manual 
interpretation of CAD and ETD spectra recorded on the above peptide esters. If necessary, 
phosphopeptide sequences were confirmed by recording tandem mass spectra on the 
corresponding synthetics. 
Epitope Prediction. This was performed using SYFPEITHI and a threshold score of 20.  
Peptides. Peptides used in this study were synthesized with Fmoc chemistry, isolated by HPLC 
to >90% purity, and validated with mass spectrometry (EZ-Biolabs and Genscript). 
HLA-phosphopeptide Tetramers. HLA tetramers were produced as described (57). 
Generation of Human Phosphopeptide-Specific CD8 Cytotoxic T-cell lines. HLA-A2 
restricted RQA(pS)IELPSMAV phosphopeptide-specific cytotoxic CD8 T-cells were generated 
from healthy donors as described previously (58). All cytokines were from PeproTech except 
where stated. Briefly, PBMCs were cultured in flat-bottom 6-well plates at 10
7
 cells per well in 
RPMI-1640 plus 10% heat-inactivated human AB serum (Biosera) (10% media). GM-CSF (800 
IU/ml) and IL-4 (1000U/mL) were added on day 0 to generate dendritic cells (DC). On day 1, a 
maturation cocktail containing 100ng/ml TNF, 100ng/ml IL-1β, 10,000IU/ml IL-6, 8000 IU/ml 
GM-CSF and 10 µg/ml PGE2 (Sigma-Aldrich) was added. On day 2, DCs were harvested and 
loaded with phosphopeptide (20µg/ml) for 4 hours in the absence of FBS or human serum. 
Following three washes, T-cells were added at a ratio of five T-cells per DC in 10% media. 
Recombinant IL-7 (10ng/ml) and IL-15 (10ng/ml) were added on day 5. On day 9, T-cells were 
harvested and re-stimulated by adding 10
7
 irradiated PBMCs and 10
6
 irradiated autologous LCLs 
pulsed with phosphopeptide with IL-7 (5ng/ml), IL-15 (5ng/ml) and IL-2 (20IU/ml). Cultures 
were re-stimulated every 7 days thereafter in the same manner. At each re-stimulation T-cells 
were enriched using either anti-CD8 microbeads (Miltenyi Biotec) or by labeling with HLA-
phosphopeptide tetramers and using anti-PE microbeads (Miltenyi Biotec).  
HLA-B7 restricted anti-phosphopeptide T-cells were grown in the absence of dendritic 
cells by plating 5x10
6
 PBMCs in 48 well plates in 10% media with individual phosphopeptides 
at 10µg/ml for 7 days without cytokines. Re-stimulations with irradiated phosphopeptide-pulsed 
autologous PBMCs took place every 7 days with cytokines added 3 days after each re-
stimulation (final concentration 20IU/ml IL-2, 5ng/ml IL-7 and 5ng/ml IL-15). Functional and 
cytotoxicity assays were then performed from day 13.  
T-cell recognition assays. For ELISpot analysis, PBMCs or CD8 T-cells were isolated fresh 
from in heparinized blood taken from healthy donors and patients. 1x10
6
 PBMCs were isolated 
from both AML patients and healthy donors and re-suspended in AIM-V media (Invitrogen) with 
10% human AB serum (Biosera) in a 96 well plate. For 7-day assays peptide or phosphopeptides 
were added individually at 10g/ml and placed at 37°C in CO2 incubator for 7 days.  For some 
experiments (figure 4b) the 7-day culture was restimulated by adding irradiated phosphopeptide-
pulsed autologous dendritic cells for a further 7-days. For the ELISpot, cells were then harvested, 
washed 4 times in AIM-V and incubated for 16 hours with either phosphopeptides (10ug/ml), 
peptides (10ug/ml), or anti-CD3 (OKT3, 100ng/ml, Mabtech). Cytokine-producing cells were 
identified as dark spots after a 15 min reaction with 5-bromo-4-chloro-3-indolyl phosphate and 
NBT by means of an alkaline phosphatase conjugate substrate (Mabtech). Spots were counted 
using an automated reader (AID-Diagnostika), and results displayed as number of spot-forming 
cells (SFC) per 10
5 
CD8 T-cells or 10
6
 PBMCs. 
For CLL patients a different approach had to be taken as PBMCs contain largely tumor 
cells. Therefore CD8 T-cells were magnetically enriched using anti-CD8 microbeads (Miltenyi 
Biotec) to a purity of >99% for both healthy donors and patients with CLL. 200,000 CD8 T-cells 
from both patients and healthy donors were used for ELISpot analysis as described above. 
Cytotoxicity assays. Cytotoxic activity was evaluated in a standard 4 hour 
51
Cr release assay, as 
previously described(57). 
Statistical Analysis 
We analyzed the data using the Kaplan-Meier for the survival rate, the unpaired t-test for two-
group comparisons. We performed the statistical analyses using Prism version 5 (GraphPad). P 
values <0.05 were considered significant. 
Ethical approval. The University of Virginia Institutional Review Board approved all protocols. 
Patients with CLL were recruited from specialist clinics at the University Hospital NHS Trust 
and Heart of England NHS Trust (Birmingham, United Kingdom). The study received approval 
from the local ethics committees at South Birmingham, Birmingham East, North, and Solihull, 
and informed written consent was obtained in accordance with the Declaration of Helsinki in all 
cases.  
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Figure legends 
Figure 1. HLA-bound phosphopeptides are differentially displayed on tumor and matched 
healthy tissue.  (a) Phosphopeptide display isolated from HLA-A2 and HLA-B7 molecules from 
11 primary tumor samples (ALL1, AML1, CLL1-4, HCL1, MCL), EBV-transformed B-cells (B-
LCL) and HLA-matched healthy tissue (T-cells, B-cells and bone marrow). Red dots and green 
dots indicate phosphopeptide antigens selected for further study in patients with CLL and AML 
respectively.  (b) Comparison of the number of individual phosphopeptides identified between 
HLA-A2 and HLA-B7 in both normal and malignant tissue.  (c) Comparison of the number of 
unique phosphopeptides identified between normal, indolent malignant and aggressive malignant 
tissue. 
Figure 2. HLA-B7 associated phosphopeptides have characteristics that distinguish them from 
non-phosphorylated peptides. (a, b) Euler diagrams depicting the distribution of HLA-B7-
restricted phosphopeptides among different leukemias and normal tissues (a) and within different 
B-cell malignancies (b).  (c,d,f) Logoplots of residue frequency at each position of all 9mer 
HLA-B7 phosphopeptides (c); 9mer non-phosphorylated HLA-B7 peptides from the 
ImmuneEpitope database (d); and predicted HLA-B7 phosphopeptide binders with a pSer at 
position 4 (f).  The position of phosphoserine for all B7-predicted binders (e). 
Figure 3. Phosphopeptide-specific T-cells from healthy donors recognize and kill leukemic 
targets. (a) Expansion of LSP-1 (RQA(pS)IELPSMAV) specific T-cells from healthy donor 
PBMCs using DCs and tetramer selection. (b,c) Peptide antigen specificity (b) and recognition 
(c) of leukemia cell lines by LSP-1-specific T-cells. (d,e) T-cell mediated killing of leukemia cell 
lines (d) or primary leukemia samples (e) by phosphopeptide-specific T-cell lines but not an 
HLA-mismatched primary tumor.  (f) NCOA1 (RPT(pS)RLNRL)-specific T-cell mediated 
killing of three HLA-matched CLL tumor samples was inhibited by adding autologous NCOA1 
loaded cold targets. 
Figure 4. Phosphopeptide-specific immunity is present in healthy individuals within the 
circulating memory T-cell compartment. (a) Marked heterogeneity of phosphopeptide-specific 
immunity in 10 healthy donors against 86 antigens revealed by 7-day ELISpot assays. (b) 
ELISpot results for immunodominant phosphopeptides directly ex vivo and following 14-days in 
vitro expansion when tetramer binding is evident. (c) Expanded T-cells do not recognize the 
unphosphorylated counterpart peptides.  (d) The relative magnitude of phosphopeptide-specific 
T-cells compared against common viral epitopes following overnight culture (n=3).  (e) Analysis 
of memory-flow-sorted CD8+ enriched T-cells by 7-day ELISpot reveal phosphopeptide-specific 
responses reside in the memory compartment. 
Figure 5. Leukemia-associated phosphopeptide-specific immunity is lacking in CLL patients.  
(a) Comparative ELISpot analysis of enriched CD8+ T-cells from patients with CLL and healthy 
donors against 12 CLL-associated antigens reveals two distinct groupings.  (b,c) Analysis of the 
average patient response against each phosphopeptide between the groups and healthy donors (b) 
reveals both Group1 (n=12) and Group2 (n=12) have suppressed phosphopeptide-immunity yet 
responses to mitogens are intact (c).  (d,e,f) Kaplan-Meier analysis of overall survival (OS, d), 
progression free survival (PFS, e) and time to first treatment (TTFT, f) is reduced in Group1 
patients, but not statistically significant.  **P < 0.01 by Student’s t test comparing average 
responses for each phosphopeptide between HD and either Group 1 or Group 2. 
 
Figure 6. Phosphopeptide-specific immunity is lacking in patients with AML and restored 
following stem cell transplantation.  (a) AML-associated phosphopeptide-specific immunity is 
lacking in AML patients in remission compared against healthy individuals using a panel of 12 
phosphopeptide antigens.  (b) Analysis of the average patient response against each 
phosphopeptide (n=12) between the groups and healthy donors reveals patients have suppressed 
immunity.  (c) Analysis of total immunity against all 12 antigens between healthy donors (n=12) 
and each patient pre- and post-transplant (n=12) reveal the recovery of AML-associated 
phosphopeptide immunity following SCT.  (d,e) Immune reconstitution of donor anti-
phosphopeptide immunity in two AML patients demonstrating large expansions of 
phosphopeptide-specific T-cells.  (f) T-cell line specific to MLL(EPR) generated from patient 
AML4 is able to kill the HLA-B7 transfected KG-1a leukemia cell line.  ***P < 0.001, 
**P<0.01 by Student’s t test. 
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Patient Time Since 
Stage at 
presentation Genetic
Time to first 
treatment
ID Sample Age Sex (Binet stage) CD38 Zap-70 aberration IgVH (days)
CLL1 890 79 A POS POS Normal UM 2387
Progressed through 
chlorambucil
Previously treated, slow progressive 
disease
Died, Chl, FC, methylpred, died of 
disease +4695
CLL2 420 71 A NEG NEG NA NA Untreated Untreated Untreated Alive day +506
CLL3 1048 64 A NEG NA NA NA 685
Progressed 301 days 
post first tx
Untreated
Alive, FCR, transformed to Hodgkins 
ABVD, day +1142
CLL4 945 75 A NEG NEG Normal M Untreated Untreated Untreated Alive day +5341
CLL5 688 63 A NEG NA NA NA Untreated Untreated Untreated Alive day +1749
CLL6 586 86 A NEG NEG Normal M 3334 Died on tx
Prior to first treatment for 
progressive disease
Died, Chl, died of disease day +3467
CLL7 359 70 A NEG NEG NA NA Untreated Untreated untreated Alive, day +1201
CLL8 359 67 A NEG NA 13q NA 1141 Not progressed
Prior to first treatment for 
progressive disease
Alive, FCR, day +1460
CLL9 897 78 A NEG NEG Normal M Untreated Untreated Untreated Alive day +6133
CLL10 1091 89 C NA NA NA NA 0 Partial response
All taken on treatment 
(chlorambucil)
Died, Chl, ?died of disease day +362
CLL11 540 65 B NEG POS NA NA 30
Progressed 631 days 
post first tx
Previously treated, progressive 
disease
Alive, Chl, FCO, day +1399
CLL12 1064 84 C NEG NEG NA NA 68 Not progressed
18/2/09 –  Prior to first treatment 
for progressive disease
6/1/10 – 4 months post treatment
Alive, Chl/R, day +1129
CLL13 523 63 A NEG NEG NA NA Untreated Untreated 6/1/10 – 4 months post treatment Alive, day +993
CLL14 579 63 A POS NEG NA M Untreated Untreated Untreated Alive day +2708
Progression free 
survival after first 
treatment Timing of sample(s) Treatment, status
IgVH, Immunoglobulin Variable Region Mutation status:- M indicates mutated; UM, unmutated; NA, not assessed; 
NA, Not available; FC, fludarabine+cyclophosphamide; FCR, fludarabine+cyclophopshamide+rituximab; FCO, fludarabine+cyclophopshamide+ofatumumab; Chl, chlorambucil; Chl/R, chlorambucil+rituximab; Methylpred, 
methylprednisolone
AML 
Patient ID Age Gender Diagnosis and Treatment Cytogenetics Transplant History Samples Analyzed GvHD ALC
Clinical Condition at the 
end of study (12/2012)
AML1 65 M AML, ADE x2 monosomy 7 MUD 21 months post SCT No 1.2 23 months post transplant: 
Death due to Relapse †
AML2 67 F AML, DAx3, CR1 normal MUD 11 months post SCT No 1.3 26 months post transplant: In 
Remission and well
AML3 64 F AML DA x2, MIDAC, CR1 FLT3pos 2 Cord Bloods 9 months post SCT No 1.3 26 months post transplant: In 
Remission and well
AML4 67 M AML MIDAC x3 CR1 normal Sibling 10 months post SCT Skin 2.3 10 months post transplant: 
Relapsed. Patient died 13 
months post trasnplant
AML5 62 F AML, DAx2, MACE normal MUD 21 months post SCT No 1.3 39 months post transplant: In 
Remission and well
AML6 65 M AML DA/Myelotarg, DA CR1 normal MUD 3 months post SCT No 1.5 3 months post transplant: 
Death †
AML7 54 F AML, AML 17 (ADE X2) CR1 monosomy 7 MUD 7 months post SCT Gut 0.9 25 months post transplant: In 
Remission and well
AML8 56 M MDS transformed to AML, [DAx2, 
MACE, MIDAC] [ARA-C], CR2
normal MUD 6 months post SCT Skin now resolved 1 25 months post transplant: In 
Remission and well
AML9 51 F MDS no treatment trisomy 6 Sibling 113 months post SCT Eyes, mouth, skin and 
liver
2.2 131 months post transplant: In 
Remission and well
AML10 66 F AML, [AML 16] [ FLAG x2] CR2 normal MUD 34 months post SCT Skin and gut 2.7 46 months post transplant: In 
Remission and well
AML11 67 F AML, [DA x2, MIDAC] [ 
FLAG/Myelotarg, FLAG] [ FLAG x 2] 
CR3
normal 2 Cord Bloods 9 months post SCT Gut 5.4 27 months post transplant: In 
Remission and well
AML12 41 M AML, DA x 2, MIDAC, CR1 normal Sibling 15 months post SCT Skin 1.8 31 months post transplant: In 
Remission and well
MUD, matched unrelated donor; ADE, Ara-C, daunorubicin, etoposide; FLAG, fludarabine, Ara-C, idarubicin; DA, daunorubicin, Ara-c; MIDAC; amsacrine, Ara-C, etoposide, mitozantrone; CR = complete remission. 
(CR1,2,3 = 1st 2nd or 3rd CR).  ALC = absolute lymphocyte count (x109/L)
